Shaperon Inc.

KOSDAQ:A378800 Stock Report

Market Cap: ₩116.4b

Shaperon Valuation

Is A378800 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A378800 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A378800's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A378800's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A378800?

Key metric: As A378800 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A378800. This is calculated by dividing A378800's market cap by their current book value.
What is A378800's PB Ratio?
PB Ratio5.7x
Book₩19.58b
Market Cap₩116.35b

Price to Book Ratio vs Peers

How does A378800's PB Ratio compare to its peers?

The above table shows the PB ratio for A378800 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.3x
A191420 TegoScience
2.3xn/a₩121.1b
A321550 TiumBio
2.4xn/a₩121.1b
A251120 BIO-FD&CLtd
1.9xn/a₩118.3b
A348150 KoBioLabs
2.7xn/a₩112.2b
A378800 Shaperon
5.7xn/a₩116.4b

Price-To-Book vs Peers: A378800 is expensive based on its Price-To-Book Ratio (5.7x) compared to the peer average (2.3x).

Price to Book Ratio vs Industry

How does A378800's PB Ratio compare vs other companies in the KR Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
A377740 BioNote
0.3xn/aUS$344.90m
A109960 AP Healthcare
0.3xn/aUS$79.63m
No more companies available in this PB range
A378800 5.7xIndustry Avg. 2.5xNo. of Companies11PB01.63.24.86.48+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: A378800 is expensive based on its Price-To-Book Ratio (5.7x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A378800's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A378800 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A378800's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

JW Pharmaceutical

₩591.4b

Manufactures and sells medicines and medical supplies in Japan and internationally.

A001060

₩23,650.00

7D

-2.9%

1Y

-20.6%

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩272,000.00

7D

-3.5%

1Y

79.4%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,540.00

7D

3.6%

1Y

n/a